Statistical results relating the type of tumor with the clinicopathological features under evaluation
| SBT/APST N (%) | Non-invasive LGSC N (%) | P value | |
| Total nmber of cases (203) | 163 (80) | 40 (20) | |
| Median age (range) | 42 (19–276) | 44 (21–76) | 0.269 |
| Median tumor size (cm) (range) | 5.8 (0.5–23) | 5.6 (0.7–28) | 0.6 |
| Laterality | <0.001 | ||
| Unilateral | 117 (71.8) | 16 (40) | |
| Bilateral | 46 (28.2) | 24 (60) | |
| Pattern of growth | 0.024 | ||
| Exophytic | 40 (24.5) | 17 (42.5) | |
| Endophytic | 123 (75.5) | 23 (57.5) | |
| Microinvasion | 16 (9.8) | 5 (12.5) | 0.572 |
| Microinvasive carcinoma | 1 (0.6%) | 6 (15%) | <0.001 |
| FIGO stage (N of cases 143) | 0.001 | ||
| Stage I | 87 (77) | 15 (50) | |
| Stage II–IV | 26 (23) | 15 (50) | |
| Implants | 0.001 | ||
| No | 87 (77) | 15 (50) | |
| Yes | 26 (23) | 15 (50) | |
| Non-invasive | 23 (20) | 9 (30) | |
| Invasive (LGSC) | 3 (2.7) | 6 (20) | |
| Endosalpingiosis | 36 (32) | 11 (37) | 0.664 |
| Lymph node involvement (52 cases) | 4 (11.8) | 3 (16.7) | 0.622 |
| Recurrence | 7 (4) | 4 (10) | 0.153 |
FIGO, International Federation of Gynecology and Obstetrics; LGSC, low-grade serous carcinoma; SBT/APST, serous borderline tumor/atypical proliferative serous tumors.